| MeSH term | MeSH ID | Detail |
|---|---|---|
| Mucinoses | D017520 | 2 associated lipids |
| Pityriasis Lichenoides | D017514 | 2 associated lipids |
| Lichen Nitidus | D017513 | 1 associated lipids |
| Lichenoid Eruptions | D017512 | 1 associated lipids |
| Pyoderma Gangrenosum | D017511 | 3 associated lipids |
| Porokeratosis | D017499 | 1 associated lipids |
| Hidradenitis Suppurativa | D017497 | 2 associated lipids |
| Hypopigmentation | D017496 | 2 associated lipids |
| Hyperpigmentation | D017495 | 11 associated lipids |
| Acneiform Eruptions | D017486 | 3 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Hernández D et al. | Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. | 2007 | Transplantation | pmid:17893603 |
| Schwartz JJ et al. | Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. | 2007 | Transplantation | pmid:17893604 |
| First MR | Transplantation in the nineties. | 1992 | Transplantation | pmid:1370734 |
| Yamagami S et al. | Mechanism of concordant corneal xenograft rejection in mice: synergistic effects of anti-leukocyte function-associated antigen-1 monoclonal antibody and FK506. | 1997 | Transplantation | pmid:9233699 |
| Khanafer A et al. | Increased nitric oxide production during acute rejection in kidney transplantation: a useful marker to aid in the diagnosis of rejection. | 2007 | Transplantation | pmid:17876269 |
| Sawabe T et al. | Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. | 1997 | Transplantation | pmid:9233725 |
| Tydén G et al. | Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. | 2007 | Transplantation | pmid:17496528 |
| Faguer S et al. | Rituximab therapy for acute humoral rejection after kidney transplantation. | 2007 | Transplantation | pmid:17496547 |
| Singh N et al. | Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. | 2000 | Transplantation | pmid:10708096 |
| Gonwa T et al. | Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. | 2003 | Transplantation | pmid:12717205 |
| Neuhaus P et al. | Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. | 1995 | Transplantation | pmid:7530868 |
| Tzakis AG et al. | Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. | 2003 | Transplantation | pmid:12717207 |
| Heeckt PF et al. | Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. | 1995 | Transplantation | pmid:7530870 |
| Dresske B et al. | WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. | 2003 | Transplantation | pmid:12717217 |
| Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
| Pescovitz MD et al. | Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. | 2009 | Transplantation | pmid:19855247 |
| Kim CD et al. | Metabonomic analysis of serum metabolites in kidney transplant recipients with cyclosporine A- or tacrolimus-based immunosuppression. | 2010 | Transplantation | pmid:20842074 |
| Miroux C et al. | In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. | 2012 | Transplantation | pmid:22743548 |
| Stegall MD et al. | Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. | 1997 | Transplantation | pmid:9422416 |
| Shihab FS et al. | Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. | 1997 | Transplantation | pmid:9422427 |
| Vu MD et al. | Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. | 1997 | Transplantation | pmid:9422432 |
| Gathogo E et al. | Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. | 2016 | Transplantation | pmid:26413990 |
| Deuse T et al. | The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. | 2004 | Transplantation | pmid:15084926 |
| Shapiro R et al. | A prospective randomized trial of FK506-based immunosuppression after renal transplantation. | 1995 | Transplantation | pmid:7533343 |
| Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
| Kasahara M et al. | Living-related liver transplantation for type II citrullinemia using a graft from heterozygote donor. | 2001 | Transplantation | pmid:11211185 |
| Ovuworie CA et al. | Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. | 2001 | Transplantation | pmid:11685108 |
| Oz HS et al. | Provocative effects of the immunosuppressants rapamycin, tacrolimus, and dexamethasone on pneumonitis in contrast to the anti- pneumonitis effects of mycophenolate mofetil. | 2001 | Transplantation | pmid:11685124 |
| Al-Uzri A et al. | Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). | 2001 | Transplantation | pmid:11579294 |
| Mourad G et al. | Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. | 2001 | Transplantation | pmid:11579299 |
| Staatz CE et al. | Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. | 2001 | Transplantation | pmid:11579300 |
| Xue F et al. | Immune cell functional assay in monitoring of adult liver transplantation recipients with infection. | 2010 | Transplantation | pmid:20010326 |
| Papadopoulos-Köhn A et al. | Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. | 2015 | Transplantation | pmid:25208324 |
| Manitpisitkul W et al. | Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. | 2009 | Transplantation | pmid:19584685 |
| Esquivel CO et al. | Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. | 1996 | Transplantation | pmid:8607198 |
| Singh N et al. | Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. | 1996 | Transplantation | pmid:8610349 |
| Jiang H et al. | Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. | 2002 | Transplantation | pmid:12085006 |
| Grudé P et al. | MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation. | 2002 | Transplantation | pmid:12085008 |
| Xu X et al. | FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506. | 2002 | Transplantation | pmid:12085010 |
| Watanabe M et al. | Efficacy of DHMEQ, a NF-κB inhibitor, in islet transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune responses and permits long-term islet allograft acceptance. | 2013 | Transplantation | pmid:23860082 |
| Lenaers JI et al. | Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients. | 2006 | Transplantation | pmid:17102764 |
| Barraclough KA et al. | NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. | 2012 | Transplantation | pmid:23095803 |
| Hirano Y et al. | The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. | 1992 | Transplantation | pmid:1279850 |
| Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
| Nogueira JM et al. | A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. | 1999 | Transplantation | pmid:10096529 |
| Shapiro R et al. | Posttransplant diabetes in pediatric recipients on tacrolimus. | 1999 | Transplantation | pmid:10096540 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| Carroll PB et al. | Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. | 1991 | Transplantation | pmid:1702911 |
| Heidt S et al. | Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. | 2008 | Transplantation | pmid:19005412 |
| Yamamoto S et al. | FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. | 2004 | Transplantation | pmid:15591950 |
| Cooper MH et al. | Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. | 1994 | Transplantation | pmid:7509089 |
| Bechstein WO et al. | Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. | 2004 | Transplantation | pmid:15114089 |
| Serón D et al. | Immunophenotype of infiltrating cells in protocol renal allograft biopsies from tacrolimus-versus cyclosporine-treated patients. | 2007 | Transplantation | pmid:17353788 |
| Lo A et al. | Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. | 2004 | Transplantation | pmid:15114090 |
| Jin S et al. | Effect of tacrolimus on the expression of macrophage scavenger and nuclear hormone receptors in THP-1-derived human macrophages. | 2004 | Transplantation | pmid:15114099 |
| Shoker A et al. | Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection. | 2000 | Transplantation | pmid:10949194 |
| Egawa H et al. | Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. | 1995 | Transplantation | pmid:7533958 |
| Straatman LP and Coles JG | Pediatric utilization of rapamycin for severe cardiac allograft rejection. | 2000 | Transplantation | pmid:10949201 |
| Burke GW et al. | Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement. | 1999 | Transplantation | pmid:10573073 |
| Wallia A et al. | Posttransplant hyperglycemia is associated with increased risk of liver allograft rejection. | 2010 | Transplantation | pmid:20098286 |
| Araki M et al. | Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. | 2006 | Transplantation | pmid:16477217 |
| Ahuja M et al. | Polyoma virus infection after renal transplantation. Use of immunostaining as a guide to diagnosis. | 2001 | Transplantation | pmid:11349723 |
| Vivarelli M et al. | Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. | 2010 | Transplantation | pmid:20098287 |
| Gallon L et al. | ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. | 2006 | Transplantation | pmid:16477235 |
| Sanchez EQ et al. | Predicting renal failure after liver transplantation from measured glomerular filtration rate: review of up to 15 years of follow-up. | 2010 | Transplantation | pmid:20098288 |
| Niioka T et al. | Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation. | 2012 | Transplantation | pmid:23073468 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Hayashi S et al. | Effect of adenovirus-mediated transfer of the CTLA4IG gene in hamster-to-rat xenotransplantation. | 2005 | Transplantation | pmid:16123724 |
| Qi S et al. | Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. | 2000 | Transplantation | pmid:10798741 |
| Borger P et al. | Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. | 2000 | Transplantation | pmid:10798763 |
| Moffatt SD et al. | STAT 6 up-regulation by FK506 in the presence of interleukin-4. | 2000 | Transplantation | pmid:10798785 |
| Wannhoff A et al. | Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. | 2014 | Transplantation | pmid:25022236 |
| Gullestad L et al. | Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. | 2010 | Transplantation | pmid:20061999 |
| Sureshkumar KK and Chopra B | In search of an optimal induction agent in kidney transplantation. | 2014 | Transplantation | pmid:24978038 |
| Ochiai T et al. | Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. | 1989 | Transplantation | pmid:2474209 |
| Ciancio G et al. | Review of major clinical trials with mycophenolate mofetil in renal transplantation. | 2005 | Transplantation | pmid:16251852 |
| Iwata H et al. | Suppression of allograft responses by combining donor alloantigen-specific intravenous presensitization with suboptimal doses of FK506. | 1993 | Transplantation | pmid:7687396 |
| Srinivas TR et al. | The impact of mycophenolate mofetil on long-term outcomes in kidney transplantation. | 2005 | Transplantation | pmid:16251854 |
| Buell JF et al. | Malignancy after transplantation. | 2005 | Transplantation | pmid:16251858 |
| Rodriguez Rilo HL et al. | Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. | 1995 | Transplantation | pmid:7539169 |
| Ochiai T et al. | Studies of the effects of FK506 on renal allografting in the beagle dog. | 1987 | Transplantation | pmid:2447688 |
| Vanrenterghem Y et al. | The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. | 2004 | Transplantation | pmid:15257032 |
| Gillard P et al. | Early alteration of kidney function in nonuremic type 1 diabetic islet transplant recipients under tacrolimus-mycophenolate therapy. | 2014 | Transplantation | pmid:24770614 |
| Brito-Costa A et al. | Factors Associated With Changes in Body Composition Shortly After Orthotopic Liver Transplantation: The Potential Influence of Immunosuppressive Agents. | 2016 | Transplantation | pmid:27136260 |
| Bazerbachi F et al. | Pancreas-after-kidney versus synchronous pancreas-kidney transplantation: comparison of intermediate-term results. | 2013 | Transplantation | pmid:23183776 |
| Gralla J and Wiseman AC | The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression. | 2010 | Transplantation | pmid:20595929 |
| Shibasaki S et al. | Immunosuppressive effects of DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway. | 2013 | Transplantation | pmid:23269193 |
| Ricordi C et al. | In vivo effect of FK506 on human pancreatic islets. | 1991 | Transplantation | pmid:1716797 |
| Tricot L et al. | Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. | 2005 | Transplantation | pmid:16371923 |
| Opelz G and Döhler B | Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients. | 2011 | Transplantation | pmid:21452411 |
| Veenhof H et al. | Clinical Validation of Simultaneous Analysis of Tacrolimus, Cyclosporine A, and Creatinine in Dried Blood Spots in Kidney Transplant Patients. | 2017 | Transplantation | pmid:27906832 |
| Jin L et al. | Effect of Conversion to CTLA4Ig on Tacrolimus-Induced Diabetic Rats. | 2018 | Transplantation | pmid:29319618 |
| Miura Y et al. | Factors increasing quantitative interstitial fibrosis from 0 hr to 1 year in living kidney transplant patients receiving tacrolimus. | 2011 | Transplantation | pmid:21452412 |
| MacPhee IA and Holt DW | A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype. | 2008 | Transplantation | pmid:18212618 |
| Puig I Marà JM et al. | Reflex sympathetic dystrophy syndrome of the lower limbs in a renal transplant patient treated with tacrolimus. | 2000 | Transplantation | pmid:10919604 |
| Tourret J et al. | Immunosuppressive Treatment Alters Secretion of Ileal Antimicrobial Peptides and Gut Microbiota, and Favors Subsequent Colonization by Uropathogenic Escherichia coli. | 2017 | Transplantation | pmid:27681266 |
| Erickson LM et al. | Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. | 2003 | Transplantation | pmid:12923448 |
| Maluccio M et al. | Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. | 2003 | Transplantation | pmid:12923450 |
| Pascher A et al. | Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. | 2003 | Transplantation | pmid:12923454 |